AMGN compared with FDMT: revenue, margins and what each company keeps, and the suppliers and customers both name

AMGNAmgen Inc

Mkt capRevenueRevenue

FDMT4D Molecular Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

AMGNAmgen Inc

FDMT4D Molecular Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

AMGN

4 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±3.7%▲+3.73%×1.00

Q2 FY26±4.1%▲+4.57%×1.12

Q1 FY26±3.9%▼−4.75%×1.23

Feb 4 '26±3.7%▲+8.15%×2.22

FDMT

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±30.9%▲+4.64%×0.15

May 8 '26±34.6%▲+2.11%×0.06

= impliedAMGN realized, solidFDMT realized, hatchedOne scale, both sides: full bar = 39%× = |realized| ÷ impliedSource: market data

Q1 FY26

±38.6%

▲+4.91%

×0.13

Jan 7 '26±18.7%▲+8.07%×0.43

AMGNAmgen Inc

460.55▲+0.06%· post 460.42

Mkt cap$249.0BRevenue$10.4BQ3 FY26Revenue$36.8BFY25

FDMT4D Molecular Therapeutics, Inc.

12.26▲+9.00%· post 12.26

ClosedNov 6 '26

Mkt cap$884.2MRevenue$4MQ2 FY26Revenue—

Compare

ClosedNov 6 '26

AMGNAmgen Inc

FDMT4D Molecular Therapeutics, Inc.

460.55▲+0.06%post 460.42

Price

12.26▲+9.00%post 12.26

$249.0B

Mkt cap

$884.2M

Q3 FY26$10.4B

Revenue

$4MQ2 FY26

FY25$36.8B

Revenue

—

AMGN460.55▲+0.06%vsFDMT12.26▲+9.00%ClosedNov 6 '26